Top

Irish Journal of Medical Science (1971 -)

25-01-2024 | Non-Hodgkin Lymphoma | Original Article

Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma

Authors: Ismail Demir, Ozden Yildirim Akan, Ferda Bilgir, Ismail Yilmaz, Giray Bozkaya, Oktay Bilgir

Published in: Irish Journal of Medical Science (1971 -)

Abstract

Background

Epiregulin is a molecule that plays a role in cell proliferation, tumor development, inflammation, and angiogenesis in malignant diseases.

Aim

Our study aims to reveal, for the first time, the predictive value of this molecule in non-Hodgkin lymphoma (NHL) and its association with disease stage, cell type, and extranodal involvement.

Methods

The study is an observational case–control trial involving 60 newly diagnosed NHL patients and 60 healthy individuals (control group) between 18 and 75 years old. Demographic characteristics of all volunteers, stages of patients’ illnesses and lymphoma cell types, hemogram, biochemistry tests, beta 2-microglobulin, C-reactive protein (CRP), and epiregulin levels were measured and statistically evaluated.

Results

Epiregulin levels were significantly higher in NHL patients compared to the control group (P < 0.0001). Similarly, a significant increase in epiregulin levels was observed in advanced NHL patients. Furthermore, the most common NHL subgroup within the NHL group, diffuse Large B Cell Lymphoma (DLBCL), and the subgroup with extranodal involvement also had significantly higher levels of epiregulin. A positive correlation was found between the epiregulin molecule and CRP, beta 2-microglobulin, and lactate dehydrogenase (LDH) levels in NHL patients.

Conclusion

Our study suggests that serum epiregulin levels, discovered to increase in NHL patients for the first time, may be an independent predictive molecule in an advanced stage, extranodal involvement, and the DLBCL subtype of this disease. Epiregulin positively correlates with prognostic molecules such as beta 2-microglobulin, LDH, and CRP. Illuminating its potential role in NHL pathogenesis could make epiregulin a vital drug target for treatment.

Cai W, Zeng Q, Zhang X et al (2021) Trends analysis of non-Hodgkin lymphoma at the national, regional, and global level, 1990–2019: results from the global burden of disease study 2019. Front Med 8:738693. https://doi.org/10.3389/fmed.2021.738693CrossRef

Armitage JO, Gascoyne RD, Lunning MA et al (2017) Non-Hodgkin lymphoma. Lancet (London, England) 390(10091):298–310. https://doi.org/10.1016/S0140-6736(16)32407-2CrossRefPubMed

Thandra KC, Barsouk A, Saginala K et al (2021) Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel, Switzerland) 9(1):5. https://doi.org/10.3390/medsci9010005CrossRef

Müller AM, Ihorst G, Mertelsmann R et al (2005) Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 84(1):1–12. https://doi.org/10.1007/s00277-004-0939-7CrossRefPubMed

Aldinucci D, Gloghini A, Pinto A et al (2010) The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 221(3):248–263. https://doi.org/10.1002/path.2711CrossRefPubMed

Toyoda H, Komurasaki T, Uchida D et al (1997) Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 326:69–75. https://doi.org/10.1042/bj3260069CrossRefPubMedPubMedCentral

Lindvall C, Hou M, Komurasaki T et al (2003) Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 63(8):1743–1747PubMed

Liebmann C (2011) EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol 331(2):222–231. https://doi.org/10.1016/j.mce.2010.04.008CrossRefPubMed

Riese DJ 2nd, Cullum RL (2014) Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 28:49–56. https://doi.org/10.1016/j.semcdb.2014.03.005CrossRefPubMed

10.

Bauer AK, Velmurugan K, Xiong KN et al (2017) Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model. Mol Carcinog 56(1):94–105. https://doi.org/10.1002/mc.22475CrossRefPubMed

11.

Charlson ME, Carrozzino D, Guidi J et al (2022) Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom 91(1):8–35. https://doi.org/10.1159/000521288CrossRefPubMed

12.

Schneider MR, Wolf E (2009) The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218(3):460–466. https://doi.org/10.1002/jcp.21635CrossRefPubMed

13.

McIntyre E, Blackburn E, Brown PJ et al (2010) The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat 122(1):105–110. https://doi.org/10.1007/s10549-009-0536-5CrossRefPubMed

14.

Hayashida T, Takahashi F, Chiba N et al (2010) HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 107(3):1100–1105. https://doi.org/10.1073/pnas.0912710107CrossRefPubMed

15.

Kometani T, Yoshino I, Miura N et al (2009) Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Lett 278(1):27–33. https://doi.org/10.1016/j.canlet.2008.12.017CrossRefPubMed

16.

Zhang J, Iwanaga K, Choi KC et al (2008) Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Philadelphia, Pa.) 1(3):201–207. https://doi.org/10.1158/1940-6207.CAPR-08-0014CrossRef

17.

Bormann F, Stinzing S, Tierling S et al (2019) Epigenetic regulation of amphiregulin and epiregulin in colorectal cancer. Int J Cancer 144(3):569–581. https://doi.org/10.1002/ijc.31892CrossRefPubMed

18.

Wang C, Long Q, Fu Q et al (2022) Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance. Oncogene 41(45):4941–4959. https://doi.org/10.1038/s41388-022-02476-7CrossRefPubMedPubMedCentral

19.

Kamimura D, Arima Y, Kohsaka H et al (2015) Temporal expression of growth factors triggered by epiregulin regulates inflammation development. J Immunol 194(3):1039–1046. https://doi.org/10.4049/jimmunol.1400562CrossRefPubMed

20.

Child JA, Spati B, Illingworth S et al (1980) Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas findings in a multicenter study and experience in selected patients. Cancer 45(2):318–326. https://doi.org/10.1002/1097-0142(19800115)45:2%3c318::aid-cncr2820450220%3e3.0.co;2-cCrossRefPubMed

21.

Wu L, Wang T, Gui W et al (2014) Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. Oncology 87(1):40–47. https://doi.org/10.1159/000362670CrossRefPubMed

22.

Taylor DS, Cheng X, Pawlowski JE et al (1999) Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci USA 96(4):1633–1638. https://doi.org/10.1073/pnas.96.4.1633CrossRefPubMedPubMedCentral

Title: Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma
Authors: Ismail Demir
Ozden Yildirim Akan
Ferda Bilgir
Ismail Yilmaz
Giray Bozkaya
Oktay Bilgir
Publication date: 25-01-2024
Publisher: Springer International Publishing
Keywords: Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Lymphoma
Published in: Irish Journal of Medical Science (1971 -)
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-024-03609-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma

Abstract

Background

Aim

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Aim

Methods

Results

Conclusion

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page